KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
Before 2028 · —
Loading selected book…
—
Stored price
Before 2028 90.5%Leader of 5 outcomes
Before 2028 90.5%Market quality
47 / 100
Low quality24h Volume
$144.4
Open interest
$11.8K
Medium open interestBid / Ask
— / —
Before 2028Spread
—
Market data
Updated 16 minutes ago
May 16, 26, 2:30 AM UTCJan 1, 27, 4:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Before 2028
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
When will Compass Pathways submit a NDA for COMP360 psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiRules
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Rules for each outcome
- Before 2028
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
- Before July 2027
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
- Before October 2027
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
- Before Mar 1, 2027
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Mar 1, 2027, then the market resolves to Yes.
- Before Jan 1, 2027
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.
